Abstract
Intraperitoneal administration of BromAc (bromelain + acetylcysteine) is currently undergoing a phase 1 clinical trial for pseudomyxoma peritonei at our institution. This study reports on analysis of routine blood parameters before and after treatment for a series of 25 patients in this trial. Blood parameters assessed included full blood count, electrolytes, urea, and creatinine, liver function tests, coagulation studies, as well as inflammatory markers (CRP). Certain parameters such as CRP, and white cell count, were significantly elevated after treatment whilst serum albumin level was reduced indicating an inflammatory reaction. However, liver enzymes, coagulation studies, and other parameters were not affected. Therefore, there are no additional safety signals evident upon analysis of routine blood parameter testing.
Highlights
Pseudomyxoma peritonei (PMP) is a syndrome characterised by mucinous ascites, secreted by tumours of primarily appendix, ovary, or of bowel origin
Patients assessed received a mean dosage of 124 mg of bromelain, and 4.9 g of acetylcysteine per treatment period
The low dose group received a mean of 64 mg of bromelain and 2.7 g of acetylcysteine
Summary
Pseudomyxoma peritonei (PMP) is a syndrome characterised by mucinous ascites, secreted by tumours of primarily appendix, ovary, or of bowel origin. It has an estimated incidence of 0.3 per 100,000 people, and a prevalence of 2 in 100,000 [1]. A multicentre registry incorporating data from 1548 patients with PMP undergoing CRS + HIPEC demonstrated 5-year survival of 58% [2]. This is a major procedure, with 33% of patients experiencing grade 3–5 morbidity [2].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
